A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

Completed · Phase 2 · Has a placebo group

Conditions studied: Muscle Spasticity

In brief

The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury

Key facts

Study ID

NCT00557973

Run by

XenoPort, Inc.

People needed

37

Starts

2007-12-01

Expected to finish

2009-04-01

Last updated by the study team

2021-02-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Spasticity secondary to traumatic spinal cord injury between C-5 and T-12 spinal cord levels, at least 12 months post-injury with a stable neurological deficit

You may not qualify if…

• Traumatic brain injury or cognitive deficit of any etiology that may influence compliance with study procedures or outcome measures

Where it is running

• Study site — Downey, California, United States
• Study site — Gilroy, California, United States
• Study site — Pasadena, California, United States
• Study site — San Jose, California, United States
• Study site — Englewood, Colorado, United States
• Study site — Miami, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Kansas City, Kansas, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.